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Abstract We have previously characterized the biogenesis of
the human CD8K protein expressed in rat epithelial cells. We
now describe the biosynthesis, post-translational maturation and
hetero-oligomeric assembly of the human CD8K/p56lck protein
complex in stable transfectants obtained from the same cell line.
There were no differences in the myristilation of p56lck, or in the
dimerization, O-glycosylation and transport to the plasma
membrane of CD8K, between cells expressing either one or both
proteins. In the doubly expressing cells, dimeric forms of CD8K
established hetero-oligomeric complexes with p56lck, as revealed
by co-immunoprecipitation assays performed with anti-CD8K
antibody. Moreover, p56lck bound in these hetero-oligomeric
complexes was endowed with auto- and hetero-phosphorylating
activity. The present study shows that: (1) the newly synthesized
p56lck binds rapidly to CD8K and most of the p56lck is bound to
CD8K at steady state; (2) CD8K/p56lck protein complexes are
formed at internal membranes as well as at the plasma
membrane; and (3) about 50% of complexed p56lck reaches the
cell surface. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
Key words: p56lck ; CD8K ; Protein expression; Interaction;
Myristilation; Phosphorylation
1. Introduction
Human CD8 is a transmembrane glycoprotein uniquely ex-
pressed on the surface of T-lymphocytes, prevalently as an
K/K homodimer, and to a lesser extent as an K/L heterodimer
[1,2]. This protein exerts a dual function. Extracellularly, it is
a T-cell co-receptor because its ectodomain binds MHC class
I protein exposed on the surface of antigen-presenting cells [3^
5]. Intracellularly, its cytosolic domain forms a stable complex
with p56lck tyrosine kinase [6,7] ; consequently the protein is
involved in the signal transduction process determined by ac-
tivation of the T-cell receptor [8,9].
p56lck belongs to the src-family of tyrosine kinases, it is
expressed only in lymphocytes, and binds the cytosolic car-
boxy-terminal tail of CD4 and CD8 through the amino-ter-
minal portion [10,11]. The amino-terminus of p56lck is myris-
tilated and may also be palmitoylated [12^15], which favors
the membrane association and the enzymatic activity of the
protein. The binding between CD4/CD8 and p56lck is stable
and is mediated by cysteine residues on both proteins
[5,16,17]. The interaction between T-cells and antigen-present-
ing cells stimulates p56lck tyrosine kinase activity, which leads
to auto- and hetero-phosphorylation [18^20]. In fact, most of
the signalling due to T-cell receptor activation would be trans-
mitted through the CD4/CD8^p56lck complex [21,22].
We previously described the biogenesis and post-transla-
tional maturation of CD8K stably expressed in the rat cell
line FRT-U10 [23]. Other studies described the route of trans-
port of p56lck to the plasma membrane and the kinetics of
p56lck association mainly with the T-cell coreceptor CD4
[24,25]. To investigate the assembly and function of the
CD8K/p56lck complex in the absence of the other proteins
that form or interact with the T-cell receptor complex, we
generated stable FRT clones in which CD8K and p56lck
form stable and enzymatically active complexes. We found
that newly synthesized p56lck binds rapidly to CD8K through-
out the exocytic pathway and about 50% of complexed p56lck
reaches the cell surface.
2. Materials and methods
2.1. Reagents
All culture reagents were supplied by Sigma (St. Louis, MO, USA).
Solid chemicals and liquid reagents were obtained from E. Merck
(Darmstadt, Germany), Farmitalia Carlo Erba (Milan, Italy), Serva
Feinbiochemica (Heidelberg, Germany); SDS was purchased from
BDH (Poole, UK). [35S]Cysteine (speci¢c activity 1000 Ci/mmol)
was obtained from Du Pont-New England Nuclear (Boston, MA,
USA); [3H]myristic acid (speci¢c radioactivity 30 Ci/mmol) was
from Amersham International, (Amersham, Bucks., UK). Mouse
monoclonal CD8 (OKT8) was supplied by Ortho (Raritan NJ,
USA). Mouse monoclonal Lck (3A5), rabbit polyclonal Lck (2102)
and mouse monoclonal p-Tyr (PY20) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Protein A^Sepharose was
from Pharmacia (Uppsala, Sweden). The ECL kit (Amersham Inter-
national) was used for the chemiluminescent detection of horseradish
peroxidase (HRP).
2.2. Cell culture and transfection
Parental FRT cells and FRT-derived clones were cultured in Coon’s
modi¢ed Ham’s F12 medium supplemented with 10% fetal calf serum
(FCS) and 100 U/ml penicillin, 50 Wg/ml streptomycin, and 2 mM L-
glutamine in a 95% air, 5% CO2 incubator. The pRc-lck expression
vector carrying the murine lck cDNA under the control of the CMV
promoter was co-transfected in FRT-U10 cells with a plasmid RSV-
igro carrying the bacterial igro gene, in FRT cells with a plasmid
RSV-neo carrying the bacterial neo gene [23,26]. Stable transformants
were selected in the presence of 250 Wg/ml igromicin-B or 600 Wg/ml
G-418, respectively. Positive clones were screened by immuno£uores-
cence, propagated and frozen in liquid nitrogen. In all experiments,
the cultured clones were used before the tenth passage after thawing.
2.3. Radioactive labeling and immunoprecipitation
The cells were allowed to grow to subcon£uence. For [35S]cysteine
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labeling, cells were ¢rst incubated for 1 h in labeling medium contain-
ing cysteine-free Dulbecco’s modi¢ed Eagle’s medium, supplemented
with 1% FCS, and then pulse-labelled for various time with the same
medium containing 100 WCi/ml [35S]cysteine. Cells were chased for
various times with labeling medium containing 10-fold excess cold
cysteine and 10 Wg/ml cycloheximide. Immunoprecipitation analyses
are described elsewhere [27]. Immunoprecipitation of CD8 present at
the plasma membrane was obtained by loading monoclonal anti-CD8
antibody on UL23 cell monolayers for 45 min at 4‡C. The antibody
was removed and the washed monolayer was then lysed and incubated
with protein A^Sepharose as described previously [27]. Cells used for
[3H]myristic acid labeling were incubated for 24 h with Dulbecco’s
modi¢ed Eagle’s medium supplemented with 1% FCS and labelled for
4 h in serum-free medium containing 200 WCi/ml [3H]myristic acid.
2.4. Immuno£uorescence, SDS^PAGE and immunoblot analysis
Indirect immuno£uorescence analysis, preparation of cell extracts,
SDS^PAGE analysis and £uorography were performed as previously
described [27]. For immunoblot analysis, equal amounts of cell ex-
tracts (100 Wg of protein/lane) were separated on 10% SDS^PAGE
and transferred to nitrocellulose ¢lters. Filters were saturated with
10% milk solution and incubated with antibody. Filters were washed
several times and incubated for 1 h at room temperature with HRP-
conjugated antibody; HRP activity was evaluated with chemilumines-
cent assays.
2.5. In vitro kinase assay
CD8K/p56lck complexes were immunoprecipitated with anti CD8
mouse monoclonal antibody OKT8. After extensive washes, the im-
munocomplexes were resuspended in 50 ml of kinase bu¡er (10 WCi of
[Q-32P]ATP, 50 WM of cold ATP, 100 WM Na-orthovanadate, 20 mM
MgCl2, 10 mM MnCl2, 0.1% Triton X-100 and 20 mM HEPES pH
7.2) [28] and incubated for 10 min at room temperature. Incubation
was stopped with 1 ml of ice-cold stopping bu¡er (20 mM HEPES pH
7.2, 0.1% Triton X-100, 100 mM Na-orthovanadate); the proteins
were precipitated in 20% trichloroacetic acid and analyzed by SDS^
PAGE and autoradiography.
3. Results
3.1. Expression of CD8K and p56lck in FRT clones
Parental FRT cells and the FRT-U10 clone, which ex-
presses high levels of CD8K [26], were transfected (see Section
2) with the pRc-p56lck expression vector carrying the murine
lck cDNA under the control of the CMV promoter. Two
representative clones were selected, ‘FL15’ and ‘UL23’, that
stably expressed p56lck alone and with CD8K, respectively.
Both proteins were associated mainly with cellular mem-
branes, particularly the plasma membrane (Fig. 1A^D). As
expected, CD8K was not required for the membrane associa-
tion of p56lck [13,29]. Indeed, the distribution of p56lck was
the same in FL15 and UL23 cells (Fig. 1E).
We next used Western immunoblotting assays to determine
whether FL15 and UL23 cells express recombinant CD8K
Fig. 1. Plasma membrane localization of CD8K and p56lck proteins in UL23 and FL15 cells. Cells were grown on glass coverslips and pro-
cessed for immuno£uorescence light microscopy as detailed in Section 2. (A^D) UL23 cells; (E) FL15 cells. (A,C) anti-CD8K monoclonal anti-
body; (B,D,E) anti-p56lck polyclonal antibody.
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and/or p56lck of the predicted molecular weight; we used the
U10 and Jurkat cell lines as control (Fig. 2A). p56lck occurred
only in UL23 and FL15 cells (Fig. 2A, lanes 3 and 5). The
apparent molecular weight of the murine p56lck expressed in
FL15 cells was similar to that of the endogenous p56lck syn-
thesized in Jurkat cells (Fig. 2A, lane 2); consequently, the
FRT clones correctly expressed exogenous p56lck. Conversely,
CD8K was expressed only in UL23 and U10 cells (Fig. 2A,
lanes 8 and 9). The two slower migrating bands (Fig. 2A,
lanes 8 and 9) were probably due to residual CD8K homo-
dimers. Similar results were obtained with immunoprecipita-
tion assays of pulse-labelled cells (data not shown).
Finally, we investigated if like lymphocytes and U10 cells
[26], UL23 cells expressed homodimeric forms of CD8K.
SDS^PAGE analysis of immunoprecipitated products with
or without reducing agents resulted in a band of about 55
kDa (the expected size for the CD8 K/K homodimer) only in
the absence of reducing agents (Fig. 2B, lanes 3 and 4). There-
fore, also in UL23 cells CD8K is assembled in homodimers
stabilized by disul¢de bonds. The pattern of CD8K matura-
tion (O-glycosylation) was identical in UL23 and U10 cells
(M.C. Pascale, unpublished results), indicating that the co-
expression of p56lck does not modify the main parameters of
CD8K biogenesis in FRT cells.
3.2. CD8K/p56lck complexes in UL23 cells
Next we examined the interaction of CD8K with p56lck in
UL23 cells (Fig. 3). Cell lysates obtained from the UL23 clone
were immunoprecipitated with anti-CD8K (lanes 1 and 4) or
anti-p56lck (lane 2). The immunoprecipitated products (lanes 1
and 2) were separated by SDS^PAGE and analyzed by West-
ern blot with anti-p56lck antibody together with total lysates
(Fig. 3, lanes 1^3). The level of precipitation with p56lck pro-
tein was similar with anti-CD8K and anti-p56lck antibody
(Fig. 3: lanes 1 and 2). This ¢nding strongly suggested that
at steady state, almost all p56lck protein was bound to CD8K.
Conversely, after immunoprecipitation with anti-p56lck, CD8
was not revealed by Western blot with anti-CD8 antibody
(data not shown). Control experiments in which immunopre-
cipitation with anti-CD8 antibody was performed with lysates
of mixed U10 and FL15 cells did not result in p56lck protein.
This indicates that CD8K/p56lck complexes were not as-
sembled after cell lysis (data not shown). Conversely, p56lck
co-immunoprecipitated from metabolically labeled cells im-
munoprecipitated with anti-CD8 monoclonal antibody (Fig.
3, lane 4). Again, monoclonal anti p56lck antibody failed to
retrieve CD8K in immunoprecipitation experiments on meta-
bolically labeled cell lysates (data not shown).
These results show that CD8K/p56lck complexes are e⁄-
ciently assembled in UL23 cells.
To establish the timing and the site of assembly of CD8K/
p56lck protein complexes UL23 cells were pulse-labelled with
[35S]cysteine, chased for di¡erent times, and processed for sur-
face immunoprecipitation with anti-CD8K antibody followed
by cell lysis and a second round of immunoprecipitation to
reach intracellularly located CD8K. The total amount of com-
plexes coimmunoprecipitated was similar during the pulse-
chase (Fig. 4A,B). About 25% of the total complexed p56lck
was present at the cell surface at the end of the pulse time
(Fig. 4C). Conversely, newly synthesized CD8K appeared lat-
er; this con¢rms the speci¢city of the immunoprecipitation
from the surface.
In conclusion, we found that newly synthesized p56lck binds
rapidly to CD8K and about 50% of complexed p56lck reaches
the cell surface.
Moreover, the time of conversion of the unglycosylated
CD8K to the fully glycosylated form (half-time of about 15
min), the appearance of CD8K at the surface (half-time of
Fig. 2. Expression of CD8K and p56lck proteins in FRT-derived
clones. (A) Aliquots of cell lysates were separated by SDS^PAGE
and analyzed by Western blot (WB) with anti-p56lck (lanes 1^5) and
anti-CD8K (lanes 6^9) polyclonal antibody. (B) Aliquots of cell ly-
sates from U10 and UL23 cells were analyzed as in A with anti-
CD8K polyclonal antibody with or without reducing agent (DTT).
Arrows indicate p56lck (lck) and CD8K (CD8). D, dimeric CD8K ;
M, monomeric CD8K.
Fig. 3. Co-immunoprecipitation of CD8K/p56lck complexes as-
sembled in UL23 cells. Aliquots of UL23 cell lysates were immuno-
precipitated (lanes 1 and 2) and analyzed by SDS^PAGE followed
by Western blot with anti-p56lck monoclonal antibody (lanes 1^3).
Lane 1, immunoprecipitation (Iptt) with anti-CD8K (pCD8) poly-
clonal antibody; lane 2, immunoprecipitation with anti-p56lck poly-
clonal antibody; lane 3, total UL23 cell lysate; lane 4, cell lysates
from UL23 cells metabolically labeled for 4 h and immunoprecipi-
tated with anti-CD8K monoclonal antibody.
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about 30^60 min) and the total amount present at steady state
at the plasma membrane (75%) were consistent with previ-
ously reported values [23,30].
3.3. Myristilation and phosphorylation of p56lck
p56lck is myristilated at its amino terminus in lymphocytes
[12], thus we investigated if this modi¢cation occurs in UL23
and FL15 cells. Parallel cultures were pulse-labelled with
[3H]myristic acid for 4 h, the cell lysates immunoprecipitated
with monoclonal antibodies anti-lck, and the immunoprecipi-
tated products analyzed by SDS^PAGE. p56lck was indeed
myristilated in both FL15 and UL23 cells (Fig. 5, lanes 1
and 2) and the covalent nature of the binding of 3H-myristic
acid to the protein backbone was demonstrated by the resis-
tance to 1 M hydroxylamine (data not shown).
Next we used a monoclonal anti-phosphotyrosine antibody
to determine the phosphorylation status of p56lck synthesized
in UL23 cells. Two assays were performed: Western immuno-
blotting on total lysates of FL15 (Fig. 5, lanes 3 and 5) and
UL23 cells (Fig. 5, lanes 4 and 6) or immunoprecipitation
followed by Western immunoblotting with polyclonal anti-
lck antibody (Fig. 5, lanes 7 and 8). Both assays demonstrated
that p56lck was tyrosine-phosphorylated in FL15 and UL23
cells. Di¡erences in the phosphorylation levels of p56lck paral-
leled the expression levels of the protein in the diverse clones
(compare Figs. 1 and 5).
Finally, we tested CD8K-bound p56lck for tyrosine kinase
activity. CD8K/p56lck complexes were immunoprecipitated
with anti-CD8 antibody, and the immunoprecipitated prod-
ucts used for an in vitro kinase assay. The major labelled
protein was p56lck (Fig. 5, lane 9), which con¢rms a signi¢cant
autophosphorylating activity. However, a smaller protein,
most likely the immunoglobulin light chain, was also labelled
(Fig. 5, lane 9), indicating that p56lck bound to CD8K also
phosphorylates exogenous substrates in vitro.
4. Discussion
We have characterized the expression and assembly of
CD8K/p56lck protein complexes in stably transfected FRT
cells. CD8K and p56lck proteins synthesized together in
UL23 cells are indistinguishable from those individually syn-
thesized in U10 and FL15 cells, respectively, and in lympho-
cytes. This observation is supported by the results of the anal-
ysis of folding, dimerization, O-glycosylation and kinetics of
transport to the plasma membrane of CD8K ; and of the myr-
istilation and hetero-phosphorylating activity of p56lck mole-
cules assembled in complex with CD8K. Finally, the bond
between the two proteins survived treatment with non-ionic
detergent, as previously described [31].
We also described the dynamics of the formation of the
complexes and the intracellular compartment where the inter-
action between CD8K and p56lck occurs in UL23 cells. The
interaction of CD8K with p56lck and the consequent tra⁄ck-
Fig. 4. Timing of complex formation by newly synthesized CD8K
and p56lck proteins. UL23 cells were pulse-labelled with [35S]cysteine
for 15 min and chased for di¡erent times as indicated. The immuno-
precipitated products were analyzed by SDS^PAGE and £uorogra-
phy. (A) surface immunoprecipitation with anti-CD8K antibody.
(B) Second round of immunoprecipitation of cell lysates with anti-
CD8K antibody to reach intracellularly located CD8K/p56lck com-
plexes. p56lck (lck) and CD8K (CD8) proteins are indicated by ar-
rows. CD8-M, mature CD8K ; CD8-U, unglycosylated precursor
CD8K. Quantitative densitometry of autoradiograms A and B:
(C) percent of total complexed p56lck (lck) and of total CD8K
(CD8) at the cell surface at the chase times indicated; (D) percent
of total complexed p56lck (lck) and of total CD8K (CD8) present in-
tracellularly at the chase times indicated. Totals were calculated by
adding surface values to intracellular values.
Fig. 5. Myristilation, tyrosine phosphorylation, and tyrosine-kinase
activity of p56lck synthesized in UL23 and FL15 cells. Parallel cul-
tures of UL23 (lanes 1) and FL15 cells (lane 2) were pulsed with
[3H]myristic acid for 4 h, lysed and immunoprecipitated with anti-
p56lck monoclonal antibody and the immunoprecipitated products
analyzed by SDS^PAGE and £uorography. Cell lysates from FL15
(lanes 3, 5, 7) and from UL23 cells (lanes 4, 6, 8) were separated by
SDS^PAGE and analyzed by Western blot (WB) with anti-phospho-
tyrosine monoclonal antibody (lanes 3^4) or with anti-p56lck poly-
clonal antibody (lanes 5 and 6). Cell lysates from FL15 (lane 7) or
from UL23 cells (lane 8) were immunoprecipitated with anti-phos-
photyrosine antibody and revealed by Western blot with anti-lck
antibody. Lane 9, UL23 cell lysate was incubated with anti-CD8K
antibody and the immunoprecipitated products tested in a kinase as-
say supplemented by [Q-32P]ATP, followed by SDS^PAGE analysis
and autoradiography.
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ing of CD8K/p56lck complexes di¡er with respect to the as-
sembly process of p56lck with CD4 in lymphocytes [24]. In
UL23 cells, newly synthesized p56lck forms complexes with
CD8K very rapidly and, most likely, p56lck binds CD8K di-
rectly at the plasma membrane. This means that p56lck inter-
acts with pre-existing CD8K molecules present throughout the
exocytic pathway. Indeed, p56lck is synthesized on free ribo-
somes in the cytosol, so it can rapidly reach any target mem-
brane of the cell.
Conversely, newly synthesized p56lck binds CD4 in intra-
cellular membranes within 10 min, and within 30^45 min all
the complexes are transported to the plasma membrane [24].
Di¡erently, we detected 25% of the total complexed newly
synthesized p56lck bound to pre-existing CD8K molecules at
the plasma membrane already at the end of the short pulse
time. This ¢nding strongly suggests that p56lck binds CD8K at
the plasma membrane.
Surprisingly, we found that even after 2 and 3 h of chase,
no more than about 50% of complexed p56lck was on the
plasma membrane versus about 75% of total CD8K on the
surface. This ¢nding suggests that p56lck has preferential bind-
ing, and/or localization (complexed with CD8K) in intracellu-
lar membranes with respect to the plasma membrane.
This preferential localization could be explained by a re-
versible binding of p56lck to CD8K, which generates a retro-
grade £ow of bound p56lck from the plasma membrane to
counteract the anterograde £ow of CD8K toward the plasma
membrane. At steady state, most of the CD8K is in the mature
form which is generated in the trans-Golgi network [23,30]
Therefore, complexed p56lck would accumulate on the intra-
cellular membranes of the late compartments of the exocytic
pathway.
In conclusion, the model system described herein has re-
vealed that p56lck binds rapidly to CD8K located at the plas-
ma membrane as well as at intracellular membranes; and that
50% of p56lck complexed with CD8K is located on the plasma
membrane. Further experiments are required to elucidate the
di¡erences in CD4 and CD8 binding to p56lck, in the trans-
port of their complexes to the cell surface and in their asso-
ciation with other components of the plasma membrane.
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